Pharmaceuticals

Abbott Labs (ABT) and AstraZeneca (AZN) recently announced that they no longer intend to continue with the development of Certriad, a fixed-dose, single pill formulation of Abbott Lab's next-generation triglyceride lowering pill, TriLipix and AstraZeneca's powerful statin drug, Crestor. The...

Amylin Pharmaceuticals, Inc. (AMLN) and partner Eli Lilly and Company (LLY) recently submitted a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) seeking a label expansion for their type II diabetes drug, Byetta. The companies are looking to get Byetta...

Amylin Pharmaceuticals, Inc. (AMLN) and partner Eli Lilly and Company (LLY) recently submitted a supplemental New Drug Application (sNDA) with the US Food and Drug Administration (FDA) seeking a label expansion for their type II diabetes drug, Byetta. The companies are looking to get Byetta...

AstraZeneca (NYSE: AZN) and Abbott Laboratories have ended their co-development license after discontinuing development of their treatment for mixed dyslipidemia.

AstraZeneca (NYSE: AZN) and Abbott Laboratories have ended their co-development license after discontinuing development of their treatment for mixed dyslipidemia.

AstraZeneca (NYSE: AZN) announced today that it has notified Abbott that it will discontinue the development of CERTRIAD, which was being investigated for the treatment of mixed dyslipidemia. This means the co-development and license agreement with Abbott will end on January 22, 2011.

Watson Pharmaceuticals (NYSE: WPI) today announced the U.S. Food and Drug Administration approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate...

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) and Eli Lilly and Company (NYSE: LLY) today announced that a supplemental New Drug Application has been submitted to the U.S. Food and Drug Administration for the expanded use of BYETTA injection as an add-on therapy to basal insulin, with or without...

Pfizer Inc (NYSE: PFE) today announced that it has submitted supplemental applications to both the United States Food and Drug Administration and the European Medicines Agency to expand the use of Prevnar 13 to adults 50 years of age and older for the prevention of pneumococcal disease caused by...

Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI) today announced that it and U.S. Bank National Association, as successor trustee under the Company's subordinated note indenture, dated as of March 23, 2006 (as amended, supplemented or otherwise modified from time to time, the "Subordinated Note...

The U.S. Food and Drug Administration today approved the vaccine Gardasil (NYSE: MRK) for the prevention of anal cancer and associated precancerous lesions due to human papillomavirus types 6, 11, 16, and 18 in people ages 9 through 26 years.

Matrixx Initiatives, Inc. (Nasdaq: MTXX) and H.I.G. Capital, LLC today announced that Wonder Holdings, Inc. and Wonder Holdings Acquisition Corp., both affiliates of H.I.G. Capital, LLC formed for the purpose of acquiring Matrixx, have commenced a tender offer to acquire all of the outstanding...

Abbott Diabetes Care (NYSE: ABT) today announced that it has initiated a recall of 359 lots (approximately 359 million strips) of Precision Xtra®, Precision Xceed Pro®, MediSense® Optium™, Optium™, OptiumEZ and ReliOn® Ultima Blood Glucose Test Strips in the United States and Puerto Rico. The test...